ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma Group International ADR is the American Depositary Receipt representing shares of a clinical-stage biotechnology company focused on developing novel small molecule therapies. The company targets cancers, chronic hepatitis B virus (HBV), and age-related diseases, primarily by inhibiting protein-protein interactions to restore apoptosis, or programmed cell death, in diseased cells. Key product candidates include HQP1351, a BCR-ABL inhibitor for certain leukemia mutants; APG-2575, a Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an MDM2-p53 interaction inhibitor; and APG-1252, a dual Bcl-2/Bcl-xL inhibitor for lung cancers and lymphomas. Additional candidates like APG-1387 for solid tumors and HBV, APG-2449 targeting specific kinases, and APG-5918 as an embryonic ectoderm development inhibitor expand its pipeline. Ascentage Pharma Group International ADR operates in discovering, developing, and commercializing these therapies, with activities spanning medical research, clinical trials, and collaborations with biotech firms and institutions. Its efforts center on unmet needs in hematological malignancies across regions including Mainland China and the United States. Founded in 2009 and headquartered in Suzhou, China, it plays a role in advancing targeted oncology and infectious disease treatments.